Science and health information analytics business Elsevier has finalised the name of six companies that will join its innovation hub for biotech and pharma start-ups, known as The Hive.

The firms selected from more than 150 applicants for the second intake to The Hive, including Exscientia, LegoChem Biosciences, 4P-Pharma, Beacon Discovery, Sigilon Therapeutics and Unum Therapeutics.

These start-ups will receive support and complimentary training for more than 18 months from Elsevier, and will work on various pharmaceutical technologies and discoveries.

They will also gain access to Elsevier’s research and development (R&D) information solutions such as Pathway Studio, Reaxys, PharmaPendium and ScienceDirect that are designed to support research during early stages of drug discovery and development.

Elsevier senior strategic marketing manager Betsy Davis said: “As the pharma ecosystem grapples with how to incorporate artificial intelligence (AI) into R&D, or how to accelerate the discovery of new biologics and immunotherapies, start-ups around the globe are playing a pivotal role.”

“We will especially focus on helping these companies close the gap between concept and commercialisation, particularly for start-ups from academic backgrounds.”

UK-based Exscientia focuses on automation of drug design by using AI-powered systems to analyse discovery data, and for designing numerous new project-specific compounds.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

LegoChem Biosciences is a South-Korean company that uses ADC platform ConjuAll to develop antibody-drug conjugates (ADC), while French 4P-Pharma aids in advancing early stage technologies from discovery stage to clinical development and commercialisation.

Of the remaining US-based firms, Beacon Discovery primarily studies the translation of G-protein coupled receptors into new therapeutic candidates, and Unum Therapeutics leverages its antibody-coupled T-cell receptor (ACTR) for the creation of new immunotherapy products.

Sigilon Therapeutics aims to develop treatments to restore health and enhance quality of life for patients suffering from chronic diseases.

Davis added: “This year, to demonstrate the vast contribution of start-ups in the origin of drug discoveries, we will especially focus on helping these companies close the gap between concept and commercialisation, particularly for start-ups from academic backgrounds.”